NASDAQ:TNDM - Tandem Diabetes Care Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $115.92
  • Forecasted Upside: 24.76 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$92.92
▲ +1.92 (2.11%)
1 month | 3 months | 12 months
Get New Tandem Diabetes Care Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TNDM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TNDM

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$115.92
▲ +24.76% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Tandem Diabetes Care in the last 3 months. The average price target is $115.92, with a high forecast of $150.00 and a low forecast of $75.00. The average price target represents a 24.76% upside from the last price of $92.92.
Buy
The current consensus among 13 investment analysts is to buy stock in Tandem Diabetes Care. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/1/2021SVB LeerinkLower Price TargetMarket Perform$115.00 ➝ $95.00Low
i
3/31/2021OppenheimerReiterated RatingBuyHigh
i
2/25/2021Lake Street CapitalBoost Price TargetBuy$137.00 ➝ $150.00High
i
12/15/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$105.00High
i
11/6/2020Raymond JamesBoost Price TargetOutperform$116.00 ➝ $124.00High
i
11/6/2020SVB LeerinkBoost Price TargetMarket Perform$120.00 ➝ $130.00High
i
11/6/2020Piper SandlerBoost Price TargetOverweight$125.00 ➝ $132.00High
i
Rating by Matthew O'Brien at Piper Sandler
9/21/2020OppenheimerReiterated RatingBuy$120.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/28/2020SVB LeerinkBoost Price TargetMarket Perform$115.00 ➝ $120.00Low
i
Rating by D. Antalffy at SVB Leerink LLC
8/20/2020Wells Fargo & CompanyInitiated CoverageOverweight$120.00High
i
7/31/2020Raymond JamesBoost Price TargetOutperform$95.00 ➝ $116.00Low
i
7/31/2020Craig HallumBoost Price TargetBuy$102.00 ➝ $140.00High
i
Rating by Alexander Nowak at Craig Hallum
7/31/2020Lake Street CapitalBoost Price TargetPositive ➝ Buy$125.00 ➝ $137.00High
i
7/31/2020SVB LeerinkBoost Price TargetMarket Perform$105.00 ➝ $115.00High
i
Rating by D. Antalffy at SVB Leerink LLC
7/31/2020GuggenheimUpgradeNeutral ➝ Buy$130.00High
i
Rating by Christopher Pasquale at Guggenheim
7/31/2020Piper SandlerBoost Price TargetOverweight$90.00 ➝ $125.00High
i
Rating by Matthew O'Brien at Piper Sandler
7/7/2020CowenBoost Price TargetPositive ➝ Outperform$85.00 ➝ $110.00Low
i
Rating by Ryan Blicker at Cowen Inc
7/6/2020CitigroupUpgradeNeutral ➝ Buy$94.00 ➝ $120.00Low
i
6/30/2020OppenheimerInitiated CoverageBuy$102.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/30/2020Piper SandlerReiterated RatingBuy$90.00Low
i
Rating by Matthew O'Brien at Piper Sandler
6/30/2020Bank of AmericaReiterated RatingHold$100.00Low
i
Rating by Travis Steed at Bank of America Co.
6/30/2020CowenReiterated RatingBuy$85.00Low
i
Rating by Ryan Blicker at Cowen Inc
6/22/2020UBS GroupBoost Price TargetBuy$98.00 ➝ $106.00Low
i
6/22/2020OppenheimerBoost Price TargetReduce ➝ Outperform$92.00 ➝ $102.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/18/2020Lake Street CapitalBoost Price Target$100.00 ➝ $125.00Low
i
6/18/2020Raymond JamesBoost Price TargetOutperform$88.00 ➝ $95.00Low
i
6/17/2020OppenheimerInitiated CoverageBuy$92.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/3/2020CitigroupBoost Price TargetAverage ➝ Neutral$81.00 ➝ $94.00Low
i
5/22/2020Bank of AmericaBoost Price TargetNeutral$85.00 ➝ $95.00Low
i
5/1/2020UBS GroupLower Price TargetBuy$100.00 ➝ $98.00High
i
5/1/2020CitigroupBoost Price TargetNeutral$74.00 ➝ $81.00High
i
5/1/2020Stifel NicolausBoost Price TargetHold$65.00 ➝ $75.00Medium
i
5/1/2020OppenheimerReiterated RatingBuy$92.00High
i
5/1/2020SVB LeerinkBoost Price TargetMarket Perform$85.00 ➝ $88.00High
i
Rating by D. Antalffy at SVB Leerink LLC
4/27/2020Raymond JamesLower Price TargetOutperform$91.00 ➝ $81.00Low
i
4/24/2020SVB LeerinkDowngradeOutperform ➝ Market PerformLow
i
Rating by D. Antalffy at SVB Leerink LLC
4/20/2020Craig HallumLower Price TargetBuy$108.00 ➝ $102.00Medium
i
Rating by Alexander Nowak at Craig Hallum
3/27/2020CitigroupLower Price TargetNeutral$89.00 ➝ $74.00High
i
3/23/2020GuggenheimDowngradeBuy ➝ NeutralHigh
i
3/4/2020CitigroupInitiated CoverageNeutral$89.00Medium
i
2/25/2020OppenheimerBoost Price Target$84.00 ➝ $97.00High
i
2/25/2020Piper SandlerBoost Price TargetOverweight$70.00 ➝ $90.00High
i
2/25/2020Craig HallumBoost Price TargetBuy$92.00 ➝ $108.00High
i
Rating by Alexander Nowak at Craig Hallum
2/25/2020Stifel NicolausBoost Price TargetHold$70.00 ➝ $77.00High
i
2/25/2020Raymond JamesBoost Price TargetOutperform$85.00 ➝ $91.00High
i
2/25/2020CowenReiterated RatingOutperform$85.00 ➝ $90.00High
i
2/13/2020CowenBoost Price TargetOutperform$70.00 ➝ $85.00Medium
i
2/12/2020Craig HallumReiterated RatingBuy$92.00High
i
Rating by Alexander Nowak at Craig Hallum
2/5/2020Raymond JamesInitiated CoverageOutperform$85.00Low
i
2/4/2020Robert W. BairdDowngradeOutperform ➝ Neutral$71.00 ➝ $75.00Low
i
12/13/2019Craig HallumReiterated RatingBuy$92.00Low
i
Rating by Alexander Nowak at Craig Hallum
10/17/2019GuggenheimInitiated CoverageBuy$76.00Low
i
10/4/2019UBS GroupUpgradeNeutral ➝ Buy$75.00Low
i
8/2/2019OppenheimerBoost Price Target$80.00 ➝ $84.00Medium
i
6/17/2019Lake Street CapitalReiterated RatingBuyMedium
i
5/17/2019Bank of AmericaReiterated RatingNeutral$65.00Medium
i
5/13/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$83.00Low
i
Rating by D. Antalffy at SVB Leerink LLC
5/1/2019OppenheimerBoost Price TargetOutperform$68.00 ➝ $80.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/1/2019Stifel NicolausBoost Price TargetHold ➝ Hold$58.00 ➝ $70.00Medium
i
5/1/2019Craig HallumReiterated RatingBuy$70.00 ➝ $84.00High
i
Rating by Alexander Nowak at Craig Hallum
4/30/2019UBS GroupBoost Price TargetNeutral ➝ Neutral$53.00 ➝ $66.00High
i
3/8/2019BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$77.00High
i
3/5/2019Bank of AmericaBoost Price TargetNeutral$59.00 ➝ $65.00Low
i
2/27/2019OppenheimerBoost Price TargetOutperform$57.00 ➝ $68.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/27/2019CowenBoost Price TargetOutperform$40.00 ➝ $60.00Medium
i
2/27/2019Craig HallumBoost Price TargetBuy$59.00 ➝ $70.00Medium
i
Rating by Alexander Nowak at Craig Hallum
2/27/2019Lake Street CapitalBoost Price TargetBuy ➝ Buy$60.00 ➝ $100.00High
i
Rating by Brooks O'Neil at Lake Street Capital
2/27/2019Piper Jaffray CompaniesUpgradeOverweight$67.00High
i
2/15/2019Robert W. BairdBoost Price TargetOutperform$46.00 ➝ $55.00Medium
i
11/27/2018UBS GroupInitiated CoverageNeutral$36.00High
i
11/21/2018Robert W. BairdUpgradeNeutral ➝ Outperform$46.00High
i
11/9/2018OppenheimerSet Price TargetBuy$57.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
11/3/2018Lake Street CapitalSet Price TargetBuy$60.00High
i
Rating by Brooks O'Neil at Lake Street Capital
11/2/2018Craig HallumSet Price TargetBuy$59.00High
i
Rating by Alexander Nowak at Craig Hallum
11/2/2018OppenheimerSet Price TargetBuy$57.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
10/15/2018Lake Street CapitalSet Price TargetBuy$60.00High
i
Rating by Brooks O'Neil at Lake Street Capital
9/26/2018Dougherty & CoBoost Price TargetBuy$45.00 ➝ $56.00Low
i
9/26/2018Piper Jaffray CompaniesReiterated RatingAbove Average ➝ Overweight$32.00 ➝ $56.00Medium
i
9/25/2018OppenheimerReiterated RatingBuy$57.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
9/20/2018Craig HallumInitiated CoverageBuy$52.00 ➝ $52.00Low
i
9/14/2018Robert W. BairdDowngradeOutperform ➝ NeutralMedium
i
9/5/2018OppenheimerSet Price TargetBuy$54.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/30/2018Berenberg BankInitiated CoverageBuy ➝ Buy$50.00High
i
8/24/2018Dougherty & CoInitiated CoverageBuy ➝ Buy$45.00High
i
8/24/2018Bank of AmericaUpgradeUnderperform ➝ Neutral$45.00High
i
8/22/2018Stifel NicolausInitiated CoverageHold$25.00 ➝ $34.00High
i
8/20/2018Lake Street CapitalBoost Price TargetBuy$35.00 ➝ $65.00Low
i
8/6/2018OppenheimerSet Price TargetBuy$31.00 ➝ $38.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
7/31/2018OppenheimerSet Price TargetBuy$31.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
7/31/2018Lake Street CapitalBoost Price TargetBuy$35.00High
i
7/31/2018Piper Jaffray CompaniesBoost Price TargetOverweight$32.00High
i
7/31/2018Stifel NicolausReiterated RatingHold ➝ Hold$7.50 ➝ $25.00High
i
7/31/2018CowenReiterated RatingBuy$28.00High
i
7/23/2018Robert W. BairdReiterated RatingBuy$31.00High
i
6/22/2018Piper Jaffray CompaniesUpgradeOverweight$25.00High
i
6/18/2018Lake Street CapitalInitiated CoverageBuy$30.00High
i
5/27/2018OppenheimerSet Price TargetBuy$15.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/21/2018OppenheimerSet Price TargetBuy$10.00 ➝ $15.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/14/2018Piper Jaffray CompaniesUpgradeNeutral ➝ OverweightHigh
i
4/6/2018OppenheimerSet Price TargetBuy$8.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
3/28/2018CowenUpgradeMarket Perform ➝ OutperformMedium
i
3/23/2018Robert W. BairdUpgradeNeutral ➝ OutperformHigh
i
3/22/2018OppenheimerReiterated RatingBuyMedium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
3/2/2018Stifel NicolausReiterated RatingHold$4.00High
i
2/27/2018CowenReiterated RatingHoldMedium
i
2/27/2018CitigroupInitiated CoverageOutperform$5.50Low
i
2/26/2018OppenheimerInitiated CoverageBuy$5.50 ➝ $6.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
11/19/2017Robert W. BairdReiterated RatingHold$3.00N/A
i
10/10/2017WedbushReiterated RatingOutperform$50.00 ➝ $17.00N/A
i
10/6/2017Piper Jaffray CompaniesReiterated RatingHold$15.00N/A
i
5/3/2017B. RileyReiterated RatingNeutral$15.00Medium
i
Rating by G. Chodaczek at B. Riley
4/28/2017B. RileyReiterated RatingNeutral$15.00Low
i
Rating by G. Chodaczek at B. Riley
4/10/2017CowenDowngradeOutperform ➝ Market Perform$15.00Medium
i
3/30/2017WedbushReiterated RatingOutperform$110.00Low
i
3/30/2017Piper Jaffray CompaniesReiterated RatingNeutral ➝ NeutralMedium
i
3/29/2017B. RileyDowngradeNeutral$15.00Medium
i
Rating by G. Chodaczek at B. Riley
3/24/2017B. RileyDowngradeBuy ➝ Neutral$50.00 ➝ $15.00Low
i
Rating by G. Chodaczek at B. Riley
3/11/2017B. RileyReiterated RatingBuy$50.00N/A
i
3/9/2017Northcoast ResearchReiterated RatingBuyN/A
i
Rating by E. Snyder at Northcoast Research
1/24/2017WedbushReiterated RatingPositiveN/A
i
11/7/2016B. RileyReiterated RatingBuy$70.00N/A
i
11/3/2016Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralN/A
i
11/2/2016B. RileyReiterated RatingBuy$70.00N/A
i
11/2/2016Deutsche Bank AktiengesellschaftLower Price TargetBuy$140.00 ➝ $90.00N/A
i
11/2/2016Feltl & Co.DowngradeStrong-Buy ➝ BuyN/A
i
Rating by B. Haynor at Feltl & Co.
11/2/2016WedbushLower Price TargetOutperform$200.00 ➝ $110.00N/A
i
11/2/2016Robert W. BairdDowngradeOutperform ➝ Neutral$110.00 ➝ $40.00N/A
i
11/2/2016Stifel NicolausDowngradeBuy ➝ Hold$150.00 ➝ $35.00N/A
i
10/2/2016B. RileyInitiated CoverageBuy$100.00N/A
i
9/26/2016B. RileyInitiated CoverageBuy$100.00N/A
i
Rating by G. Chodaczek at B. Riley
7/29/2016WedbushReiterated RatingOutperform$200.00N/A
i
6/15/2016WedbushReiterated RatingOutperform$200.00N/A
i
5/16/2016Sterne Agee CRTReiterated RatingNeutralN/A
i
Rating by G. Chodaczek at Sterne Agee CRT
5/2/2016Robert W. BairdReiterated RatingBuyN/A
i
4/21/2016Piper Jaffray CompaniesReiterated RatingBuy$120.00N/A
i
Rating by Brooks West at Piper Jaffray Companies
(Data available from 4/21/2016 forward)
Tandem Diabetes Care logo
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $92.92
$90.67
$93.08

50 Day Range

MA: $87.78
$81.28
$95.83

52 Week Range

Now: $92.92
$68.00
$123.74

Volume

550,791 shs

Average Volume

774,395 shs

Market Capitalization

$5.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Tandem Diabetes Care?

The following Wall Street research analysts have issued stock ratings on Tandem Diabetes Care in the last year: Bank of America Co., Citigroup Inc., Cowen Inc, Craig Hallum, Guggenheim, Lake Street Capital, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Stifel Nicolaus, SVB Leerink LLC, UBS Group AG, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for TNDM.

What is the current price target for Tandem Diabetes Care?

13 Wall Street analysts have set twelve-month price targets for Tandem Diabetes Care in the last year. Their average twelve-month price target is $115.92, suggesting a possible upside of 24.8%. Lake Street Capital has the highest price target set, predicting TNDM will reach $150.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $75.00 for Tandem Diabetes Care in the next year.
View the latest price targets for TNDM.

What is the current consensus analyst rating for Tandem Diabetes Care?

Tandem Diabetes Care currently has 4 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TNDM will outperform the market and that investors should add to their positions of Tandem Diabetes Care.
View the latest ratings for TNDM.

What other companies compete with Tandem Diabetes Care?

How do I contact Tandem Diabetes Care's investor relations team?

Tandem Diabetes Care's physical mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company's listed phone number is 858-366-6900 and its investor relations email address is [email protected] The official website for Tandem Diabetes Care is www.tandemdiabetes.com.